The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC).
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Celgene
 
Emmet Jordan
No Relationships to Disclose
 
Yelena Kemel
Employment - BioReference Laboratories
 
Semanti Mukherjee
No Relationships to Disclose
 
Andrea Cercek
No Relationships to Disclose
 
Nancy E. Kemeny
No Relationships to Disclose
 
Anna M. Varghese
Consulting or Advisory Role - Cancer Genetics (I); Sequenom (I)
Research Funding - BioMed Valley Discoveries (Inst); Lilly (Inst); Verastem (Inst)
 
Matthew Rusek
No Relationships to Disclose
 
Taryn Mary Boucher
No Relationships to Disclose
 
Diana Mandelker
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Cancer Genetics; Sequenom
 
Ryan Ptashkin
No Relationships to Disclose
 
David Michael Hyman
Consulting or Advisory Role - Atara Biotherapeutics; Chugai Pharma; CytomX Therapeutics
Research Funding - AstraZeneca; Puma Biotechnology
 
David Klimstra
No Relationships to Disclose
 
Leonard Saltz
Consulting or Advisory Role - Abbvie; Lilly; McNeil PPC (I)
Research Funding - Taiho Pharmaceutical
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; McKesson
Research Funding - AbbVie (Inst); AstraZeneca (Inst); Biomarin (Inst); Medivation (Inst); Myriad Genetics (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Allergan (I); Genentech/Roche (I); Optos (I); Regeneron (I)
 
Kenneth Offit
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris